Amarin (AMRN)
(Delayed Data from NSDQ)
$0.59 USD
-0.01 (-1.80%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $0.60 +0.01 (1.16%) 7:14 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.59 USD
-0.01 (-1.80%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $0.60 +0.01 (1.16%) 7:14 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum C VGM
Zacks News
Amarin's (AMRN) Q1 Loss In Line With Estimates, Sales Beat
by Zacks Equity Research
Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa.
Amarin (AMRN) Meets Earnings Estimates in Q1, Revenues Tops
by Zacks Equity Research
Amarin's (AMRN) first quarter earnings were in line with expectations. However, sales beats estimates. Stock down.
Is a Beat in Store for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.
Is Amarin (AMRN) Stock a Solid Choice Right Now?
by Zacks Equity Research
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amarin's Stock Plunges Following Unfavorable Patent Ruling
by Zacks Equity Research
Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.
Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) strong revenue growth in the fourth quarter is driven by solid demand for its cardiovascular drug, Vascepa.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed the most recent trading day at $18.72, moving -0.58% from the previous trading session.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $19.04, marking a -1.4% move from the previous day.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $19.40 in the latest trading session, marking a +0.41% move from the prior day.
AstraZeneca to End Phase III Study on Fish Oil Heart Drug
by Zacks Equity Research
AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee
AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down
by Zacks Equity Research
AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.
BioMarin (BMRN) Catches Eye: Stock Jumps 5.8%
by Zacks Equity Research
BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Applied Therapeutics Up on Positive Galactosemia Study Data
by Zacks Equity Research
Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.
Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease
by Zacks Equity Research
Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.
Why Amarin (AMRN) Stock Might be a Great Pick
by Zacks Equity Research
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.
Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% Higher
by Zacks Equity Research
Acorda Therapeutics (ACOR) shares rose nearly 6% in the last trading session, amid huge volumes.
aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma
by Zacks Equity Research
aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $21.23, marking a +1.34% move from the previous day.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day